{"entity":{"id":"nct03093688","kind":"trial","name":"Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor","aka":[],"tldr":"A phase 1/2 trial in pancreatic cancer, run by Shanghai Public Health Clinical Center, now recruiting.","summary":"Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor is a phase 1/2, interventional study registered as NCT03093688 by Shanghai Public Health Clinical Center, with a registry enrolment figure of 40 participants, started 2017-03-01 and due to reach its primary completion in 2030-12-31. Interventions recorded: Infusion of iNKT cells and CD8+T cells. Conditions listed: Non-small Cell Lung Cancer; Small Cell Lung Cancer; Pancreas Cancer; Hepatocellular Carcinoma; Gastric Cancer; Renal Cell Carcinoma. Primary outcome: Incidence of adverse events related to the infusion of cells; Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: \"* Histological or cytologically diagnosis of advanced lung cancer, or advanced gastric cancer, or advanced pancrease cancer, or hepatocellular carcinoma, or advanced colorectal cancer\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03093688","url":"https://clinicaltrials.gov/study/NCT03093688"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03093688","phase":"1/2","setting":"Phace I and II Study of Immunotherapy Strategy Used iNKT Cells and CD8+T Cells in Patients With Advanced Tumor","sponsor":"Shanghai Public Health Clinical Center","participation":[{"nct":"NCT03093688","source":"https://clinicaltrials.gov/study/NCT03093688","fetchedAt":"2026-10-07T16:52:56.441Z","studySha256":"f2d14e3db73a46596275d68a042c987b15e75e5b40c462cc37da31341f0a4b9e","overallStatus":"RECRUITING","lastUpdatePosted":"2025-07-02","leadSponsor":"Shanghai Public Health Clinical Center","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":40,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2017-03-01","startedType":"actual","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03093688/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}